HIV Drugs: Medicare Part D Spending

• 50medicines with Part D spending (calendar year 2024)

Each number has its full source under its own list below.

1. 1TriumeqAbacavir/Dolutegravir/Lamivudi · $123.56 per unit$565.9 million
2. 2DescovyEmtricitabine/Tenofov Alafenam · $72.19 per unit$544.7 million
3. 3SymtuzaDarunavir/Cob/Emtri/Tenof Alaf · $154.88 per unit$448.5 million
4. 4PrezcobixDarunavir/Cobicistat · $81.22 per unit$255.4 million
5. 5CabenuvaCabotegravir/Rilpivirine · $1,079.10 per unit$211.6 million
6. 6VemlidyTenofovir Alafenamide · $47.42 per unit$199 million
7. 7IsentressRaltegravir Potassium · $33.14 per unit$112.7 million
8. 8PifeltroDoravirine · $58.16 per unit$78.7 million
9. 9DarunavirDarunavir · $24.10 per unit$43.7 million
10. 10PrezistaDarunavir · $53.75 per unit$24.7 million
11. 11EdurantRilpivirine HCl · $48.47 per unit$23.9 million
12. 12Isentress HdRaltegravir Potassium · $33.08 per unit$23 million
13. 13EtravirineEtravirine · $15.66 per unit$22.6 million
14. 14Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) · $7.05 per unit$20.9 million
15. 15MaravirocMaraviroc · $18.97 per unit$18.7 million

Source: Centers for Medicare & Medicaid Services, Medicare Part D Spending by Drug, calendar year 2024. Retrieved 12 Nov 2026.

• People living with HIV (ages 15–49)
• New HIV infections
• Clinical trials: HIV

• Infectious diseases
• Oncology
• Women's health
• Pediatric
• Hepatitis
• Mental health
• Cardiovascular
• Diabetes
• Tuberculosis
• Maternal